71 related articles for article (PubMed ID: 21650226)
1. Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors.
Wu Y; Karna S; Choi CH; Tong M; Tai HH; Na DH; Jang CH; Cho H
J Med Chem; 2011 Jul; 54(14):5260-4. PubMed ID: 21650226
[TBL] [Abstract][Full Text] [Related]
2. Wound healing effects of new 15-hydroxyprostaglandin dehydrogenase inhibitors.
Piao YL; Seo SY; Lim SC; Cho H
Prostaglandins Leukot Essent Fatty Acids; 2014 Dec; 91(6):325-32. PubMed ID: 25458900
[TBL] [Abstract][Full Text] [Related]
3. Control of the intracellular levels of prostaglandin E₂ through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing.
Choi D; Piao YL; Wu Y; Cho H
Bioorg Med Chem; 2013 Aug; 21(15):4477-84. PubMed ID: 23791868
[TBL] [Abstract][Full Text] [Related]
4. The wound-healing effect of 7,3',4'-trimethoxyflavone through increased levels of prostaglandin E
Sun KH; Karna S; Moon YS; Cho H; Choi CH
Biotechnol Lett; 2017 Oct; 39(10):1575-1582. PubMed ID: 28664315
[TBL] [Abstract][Full Text] [Related]
5. Effect of 15-hydroxyprostaglandin dehydrogenase inhibitor on wound healing.
Seo SY; Han SI; Bae CS; Cho H; Lim SC
Prostaglandins Leukot Essent Fatty Acids; 2015 Jun; 97():35-41. PubMed ID: 25899574
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors.
Wu Y; Tai HH; Cho H
Bioorg Med Chem; 2010 Feb; 18(4):1428-33. PubMed ID: 20122835
[TBL] [Abstract][Full Text] [Related]
7. Cell-based biological evaluations of 5-(3-bromo-4-phenethoxybenzylidene)thiazolidine-2,4-dione as promising wound healing agent.
Piao YL; Ram Song A; Cho H
Bioorg Med Chem; 2015 May; 23(9):2098-103. PubMed ID: 25801150
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
Tong M; Ding Y; Tai HH
Carcinogenesis; 2006 Nov; 27(11):2170-9. PubMed ID: 16632868
[TBL] [Abstract][Full Text] [Related]
9. Effect of thiazolidinedione phenylacetate derivatives on wound-healing activity.
Park SH; Choi D; Cho H
Arch Pharm Res; 2019 Sep; 42(9):790-814. PubMed ID: 29948772
[TBL] [Abstract][Full Text] [Related]
10. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128
[TBL] [Abstract][Full Text] [Related]
11. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
[TBL] [Abstract][Full Text] [Related]
12. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Ding Y; Tong M; Liu S; Moscow JA; Tai HH
Carcinogenesis; 2005 Jan; 26(1):65-72. PubMed ID: 15358636
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
Cho H; Tai HH
Arch Biochem Biophys; 2002 Sep; 405(2):247-51. PubMed ID: 12220539
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
Duveau DY; Yasgar A; Wang Y; Hu X; Kouznetsova J; Brimacombe KR; Jadhav A; Simeonov A; Thomas CJ; Maloney DJ
Bioorg Med Chem Lett; 2014 Jan; 24(2):630-5. PubMed ID: 24360556
[TBL] [Abstract][Full Text] [Related]
15. Regulation of prostaglandin transporters in colorectal neoplasia.
Holla VR; Backlund MG; Yang P; Newman RA; DuBois RN
Cancer Prev Res (Phila); 2008 Jul; 1(2):93-9. PubMed ID: 19138942
[TBL] [Abstract][Full Text] [Related]
16.
Karna S
Pharmacogn Mag; 2017 Jan; 13(Suppl 1):S122-S126. PubMed ID: 28479736
[TBL] [Abstract][Full Text] [Related]
17. Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase.
Yao B; Xu J; Harris RC; Zhang MZ
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F433-9. PubMed ID: 18057186
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of 15-hydroxyprostaglandin dehydrogenase by 9,11-deoxyprostaglandins in vitro and in vivo.
Yamazaki M; Ohuchi K; Sasaki M; Sakai K
Mol Pharmacol; 1981 May; 19(3):456-62. PubMed ID: 7266469
[No Abstract] [Full Text] [Related]
19. Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene.
Li M; Xie J; Cheng L; Chang B; Wang Y; Lan X; Zhang D; Yin Y; Cheng N
Cancer Invest; 2008 Nov; 26(9):905-12. PubMed ID: 19034772
[TBL] [Abstract][Full Text] [Related]
20. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer.
Liu Z; Wang X; Lu Y; Han S; Zhang F; Zhai H; Lei T; Liang J; Wang J; Wu K; Fan D
Carcinogenesis; 2008 Jun; 29(6):1219-27. PubMed ID: 18174234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
